Non-mutagenic impurities: more guidance needed on safety-based limits
More guidance is needed on the appropriate control of non-mutagenic…
More guidance is needed on the appropriate control of non-mutagenic impurities during clinical development, explains Dave P Elder, JPAG Member and pharmaceutical industry consultant, in this audio interview.